1. Home
  2. BILL vs SRRK Comparison

BILL vs SRRK Comparison

Compare BILL & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

HOLD

Current Price

$53.49

Market Cap

5.0B

Sector

Technology

ML Signal

HOLD

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

HOLD

Current Price

$44.98

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BILL
SRRK
Founded
2006
2012
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.6B
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
BILL
SRRK
Price
$53.49
$44.98
Analyst Decision
Buy
Strong Buy
Analyst Count
22
9
Target Price
$61.05
$47.00
AVG Volume (30 Days)
2.4M
2.1M
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,499,861,000.00
N/A
Revenue This Year
$12.06
N/A
Revenue Next Year
$13.30
$20,271.77
P/E Ratio
N/A
N/A
Revenue Growth
11.63
N/A
52 Week Low
$36.55
$22.71
52 Week High
$100.19
$46.98

Technical Indicators

Market Signals
Indicator
BILL
SRRK
Relative Strength Index (RSI) 64.73 69.88
Support Level $49.51 $39.51
Resistance Level $50.26 $43.94
Average True Range (ATR) 1.73 2.25
MACD 0.54 0.56
Stochastic Oscillator 92.62 91.11

Price Performance

Historical Comparison
BILL
SRRK

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

Share on Social Networks: